Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
Date:11/14/2013

, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).  DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme patients. 

About Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Approximately 15,000 people are diagnosed with glioblastoma each year in the U.S., with similar incidence in Europe. Standard of care is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy with temozolomide. Approximately 60 percent of GBM patients treated with temozolomide experience tumor progression within one year. More than half of glioblastoma patients will fail the currently approved therapies.

About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For more information, please visit www.delmarpharma.com or follow us on Twitter @delmarpharma or Facebook.com/delmarpharma.

Safe Harbor Statement
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... 2014 "The uglier, the better," says Dr. ... is full of laughter as we enjoy the ugly sweater ... a sweater from scratch. " It was a sight to ... that weren't ridiculous enough, the Christmas balls were faces of ... those interested in participating this year, it's simple to get ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... to a hundred years ago are being used in the ... the first time old bones have been used in this ... combination of latest computer modelling techniques developed at the University ... of Bristol. With Engineering and Physical Sciences Research Council ...
... core professional obligation and lying, even for a patient, ... Jr., MD, FACP, president of the American College of ... internal medicine physician and medical student members today. ... "sick notes" issued without a medical evaluation to some ...
... HealthDay Reporter , MONDAY, Feb. 28 (HealthDay News) ... in which inflammation of the lining of the nose and ... the most severe cases, patients develop nasal polyps that can ... to begin with a steroid nasal spray and then move ...
... , MONDAY, Feb. 28 (HealthDay News) -- Few things send ... rising temperature. But, a new report from the American ... reminding parents that a fever is usually just the body,s ... actually prolong an illness. The AAP recommends that, in ...
... , MONDAY, Feb. 28 (HealthDay News) -- Heart ... positive outlook, researchers are reporting. More than 2,800 heart ... their belief in their ability to recover from the illness ... 1,637 of the patients had died. Of those deaths, 885 ...
... MONDAY, Feb. 28 (HealthDay News) -- The stress of ... and gain weight, researchers report. The Georgia Health ... 60 first-time mothers who were asked about their levels ... a low amount of physical activity, was most influenced ...
Cached Medicine News:Health News:Learning from old bones to treat modern back pain 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 3Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Stress May Help Spur Weight Gain in New Moms, Study Finds 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: